477.1K
XNAS Volume
High volume today
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Evert B. Schimmelpennink | Director, President, CEO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 4,200 | 337,906 | - | - | Stock Option (right to buy) | |
| Evert B. Schimmelpennink | Director, President, CEO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 07 Mar 2025 | 4,200 | 49,200 | - | 1.0 | 4,368 | Common Stock |
| Marc Odrich | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 80,100 | 80,100 | - | - | Stock Option (right to buy) | |
| Shawn Olsson | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 80,100 | 80,100 | - | - | Stock Option (right to buy) | |
| Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 279,100 | 279,100 | - | - | Stock Option (right to buy) | |
| Daniel R. Chevallard | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 70,444 | 70,444 | - | - | Stock Option (right to buy) | |
| Shawn Olsson | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 16 Dec 2024 | 3,333 | 3,333 | - | 2.1 | 6,933 | Common Stock |
| Shawn Olsson | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 3,333 | 64,641 | - | - | Stock Option (right to buy) | |
| Evert B. Schimmelpennink | Director, President, CEO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2024 | 45,000 | 342,106 | - | - | Stock Option (right to buy) | |
| Evert B. Schimmelpennink | Director, President, CEO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 22 Jul 2024 | 45,000 | 45,000 | - | 1.0 | 46,800 | Common Stock |
| Daniel R. Chevallard | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 15.68 per share. | 14 May 2024 | 3,188 | 3,188 | - | 15.7 | 49,988 | Common Stock |
| James McCollum | Director | Purchase of securities on an exchange or from another person at price $ 15.99 per share. | 13 May 2024 | 31,332 | 525,565 | - | 16.0 | 501,093 | Common Stock |
| James McCollum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 477,600 | 477,600 | - | 0 | Common Stock | |
| James McCollum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Marc Odrich | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Marc Odrich | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 99,599 | 99,599 | - | 0 | Common Stock | |
| Marc Odrich | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 66,472 | 66,472 | - | - | Stock Option (right to buy) | |
| Daniel R. Chevallard | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Frederic Guerard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Kimberlee Cobleigh Drapkin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 387,106 | 387,106 | - | - | Stock Option (right to buy) | |
| Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 475,000 | 475,000 | - | - | Stock Option (right to buy) | |
| Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 82,723 | 82,723 | - | - | Stock Option (right to buy) | |
| Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 315,864 | 315,864 | - | - | Stock Option (right to buy) | |
| Zachary Scheiner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Frederic Guerard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 30,897 | 30,897 | - | - | Stock Option (right to buy) | |
| Frederic Guerard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 23,571 | 23,571 | - | - | Stock Option (right to buy) | |
| Shelley B. Thunen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Shawn Olsson | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 50,915 | 50,915 | - | - | Stock Option (right to buy) | |
| Shawn Olsson | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Shawn Olsson | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 67,974 | 67,974 | - | - | Stock Option (right to buy) | |
| Shawn Olsson | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 30,466 | 30,466 | - | - | Stock Option (right to buy) | |
| James McCollum | Director | Grant, award, or other acquisition of securities at price $ 15.03 per share. | 21 Mar 2024 | 16,633 | 494,233 | - | 15.0 | 249,992 | Common Stock |
| James McCollum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 95,034 | 95,034 | - | 0 | Common Stock | |
| James McCollum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 6,575 | 6,575 | - | - | Warrant (right to buy) |